SCHEMBL13625216

SCHEMBL13625216

CC1(C)CCC1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26088608 1.00
Hydrochloric Acid SCHEMBL28115986 0.97
SCHEMBL5868448 0.80 LMNA (0.39)
SCHEMBL27981525 0.80 CYP3A4 (0.39)
SCHEMBL18029933 0.78
SCHEMBL17971806 0.78
SCHEMBL1660636 0.78
SCHEMBL7739770 0.78 TRPA1 (0.32)
SCHEMBL8984298 0.76
SCHEMBL12166986 0.76 IDO1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3394068-A1 TDO2 INHIBITORS Genentech, Inc. (US) 2018-10-31 EP claimed
WO-2017107979-A1 TDO2 INHIBITORS GENENTECH, INC. (US) 2017-06-29 WO claimed
US-12391802-B2 Method of forming semicrystalline polyetherimide, and polyetherimide-containing composition SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2025-08-19 US disclosed
US-20240317706-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-26 US disclosed
EP-3394068-B1 TDO2 INHIBITORS GENENTECH INC (US) 2024-09-11 EP disclosed
CN-117858865-A CBL-B modulators and uses thereof 林伯士克莱奥公司 2024-04-09 CN disclosed
CN-113166151-B Substituted xanthine derivatives 勃林格殷格翰国际有限公司 2023-12-01 CN disclosed
EP-3894410-B1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INT (DE) 2023-10-11 EP disclosed
WO-2023069720-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2023-04-27 WO disclosed
CN-113748155-B Methods of forming semi-crystalline polyetherimides and compositions comprising polyetherimides 高新特殊工程塑料全球技术有限公司 2022-07-22 CN disclosed
US-20220177479-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-06-09 US disclosed
EP-3894410-A1 SUBSTITUTED XANTHINE DERIVATIVES Boehringer Ingelheim International GmbH (DE) 2021-10-20 EP disclosed
CN-113166151-A Substituted xanthine derivatives 勃林格殷格翰国际有限公司 2021-07-23 CN disclosed
WO-2020234683-A1 METHOD OF FORMING SEMICRYSTALLINE POLYETHERIMIDE, AND POLYETHERIMIDE-CONTAINING COMPOSITION SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2020-11-26 WO disclosed
EP-3741792-A1 METHOD OF FORMING SEMICRYSTALLINE POLYETHERIMIDE, AND POLYETHERIMIDE-CONTAINING COMPOSITION SABIC Global Technologies B.V. (NL) 2020-11-25 EP disclosed
WO-2020120450-A1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-06-18 WO disclosed
US-20200190093-A1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-06-18 US disclosed
EP-3394068-A1 TDO2 INHIBITORS Genentech, Inc. (US) 2018-10-31 EP disclosed
WO-2017107979-A1 TDO2 INHIBITORS GENENTECH, INC. (US) 2017-06-29 WO disclosed
US-20090286958-A1 INTERFERON-BETA FUSION PROTEINS AND USES BIOGEN IDEC MA INC. (US) 2009-11-19 US disclosed